Literature DB >> 10085223

Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q).

M F Vickers1, R S Mani, M Sundaram, D L Hogue, J D Young, S A Baldwin, C E Cass.   

Abstract

We have produced recombinant human equilibrative nucleoside transporter (hENT1) in the yeast Saccharomyces cerevisiae and have compared the binding of inhibitors of equilibrative nucleoside transport with the wild-type transporter and a N-glycosylation-defective mutant transporter. Equilibrium binding of 3H-labelled nitrobenzylmercaptopurine ribonucleoside {6-[(4-nitrobenzyl)thio]-9-beta-d-ribofuranosyl purine; NBMPR} to hENT1-producing yeast revealed a single class of high-affinity sites that were shown to be in membrane fractions by (1) equilibrium binding (means+/-S.D.) of [3H]NBMPR to intact yeast (Kd 1.2+/-0.2 nM; Bmax 5.0+/-0.5 pmol/mg of protein) and membranes (Kd 0.7+/-0.2 nM; Bmax 6.5+/-1 pmol/mg of protein), and (2) reconstitution of hENT1-mediated [3H]thymidine transport into proteoliposomes that was potently inhibited by NBMPR. Dilazep and dipyridamole inhibited NBMPR binding to hENT1 with IC50 values of 130+/-10 and 380+/-20 nM respectively. The role of N-linked glycosylation in the interaction of NBMPR with hENT1 was examined by the quantification of binding of [3H]NBMPR to yeast producing either wild-type hENT1 or a glycosylation-defective mutant (hENT1/N48Q) in which Asn-48 was converted into Gln. The Kd for binding of NBMPR to hENT1/N48Q was 10. 5+/-1.6 nM, indicating that the replacement of an Asn residue with Gln decreased the affinity of hENT1 for NBMPR. The decreased affinity of hENT1/N48Q for NBMPR was due to an increased rate of dissociation (koff) and a decreased rate of association (kon) of specifically bound [3H]NBMPR because the values for hENT1-producing and hENT1/N48Q-producing yeast were respectively 0.14+/-0.02 and 0. 36+/-0.05 min-1 for koff, and (1.2+/-0.1)x10(8) and (0.40+/-0. 04)x10(8) M-1.min-1 for kon. These results indicated that the conservative conversion of an Asn residue into Gln at position 48 of hENT1 and/or the loss of N-linked glycosylation capability altered the binding characteristics of the transporter for NBMPR, dilazep and dipyridamole.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085223      PMCID: PMC1220123     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  45 in total

1.  Functional complementation of a membrane transport deficiency in Saccharomyces cerevisiae by recombinant ND4 fusion protein.

Authors:  D L Hogue; M J Ellison; M Vickers; C E Cass
Journal:  Biochem Biophys Res Commun       Date:  1997-09-29       Impact factor: 3.575

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine.

Authors:  M W Ritzel; S Y Yao; A M Ng; J R Mackey; C E Cass; J D Young
Journal:  Mol Membr Biol       Date:  1998 Oct-Dec       Impact factor: 2.857

4.  Functional reconstitution of pharmacologically distinct subtypes of nucleoside transporters in liposomal membranes.

Authors:  J R Hammond
Journal:  J Pharmacol Exp Ther       Date:  1994-11       Impact factor: 4.030

5.  Nucleoside transport in human and sheep erythrocytes. Evidence that nitrobenzylthioinosine binds specifically to functional nucleoside-transport sites.

Authors:  S M Jarvis; J D Young
Journal:  Biochem J       Date:  1980-08-15       Impact factor: 3.857

6.  Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs.

Authors:  M Sundaram; S Y Yao; A M Ng; M Griffiths; C E Cass; S A Baldwin; J D Young
Journal:  J Biol Chem       Date:  1998-08-21       Impact factor: 5.157

7.  Nitrobenzylthioinosine-sensitive nucleoside transport system: mechanism of inhibition by dipyridamole.

Authors:  S M Jarvis
Journal:  Mol Pharmacol       Date:  1986-12       Impact factor: 4.436

8.  Enzymic cleavage as a probe of the molecular structures of mammalian equilibrative nucleoside transporters.

Authors:  F Y Kwong; J S Wu; M M Shi; H E Fincham; A Davies; P J Henderson; S A Baldwin; J D Young
Journal:  J Biol Chem       Date:  1993-10-15       Impact factor: 5.157

9.  Initial rate kinetics of the transport of adenosine and 4-amino-7-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (tubercidin) in cultured cells.

Authors:  E R Harley; A R Paterson; C E Cass
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

10.  Erythrocyte nucleoside transport: asymmetrical binding of nitrobenzylthioinosine to nucleoside permeation sites.

Authors:  S M Jarvis; D McBride; J D Young
Journal:  J Physiol       Date:  1982-03       Impact factor: 5.182

View more
  26 in total

Review 1.  Glycosylation of solute carriers: mechanisms and functional consequences.

Authors:  Nis Borbye Pedersen; Michael C Carlsson; Stine Falsig Pedersen
Journal:  Pflugers Arch       Date:  2015-09-18       Impact factor: 3.657

2.  Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4).

Authors:  Chunmei Wang; Wenwei Lin; Hilaire Playa; Shan Sun; Keyuna Cameron; John K Buolamwini
Journal:  Biochem Pharmacol       Date:  2013-09-07       Impact factor: 5.858

3.  Novel nuclear hENT2 isoforms regulate cell cycle progression via controlling nucleoside transport and nuclear reservoir.

Authors:  Natalia Grañé-Boladeras; Christopher M Spring; W J Brad Hanna; Marçal Pastor-Anglada; Imogen R Coe
Journal:  Cell Mol Life Sci       Date:  2016-06-06       Impact factor: 9.261

Review 4.  Equilibrative nucleoside transporters-A review.

Authors:  Rebba C Boswell-Casteel; Franklin A Hays
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2016-10-19       Impact factor: 1.381

5.  Cysteine-accessibility analysis of transmembrane domains 11-13 of human concentrative nucleoside transporter 3.

Authors:  Jing Zhang; Tracey Tackaberry; Mabel W L Ritzel; Taylor Raborn; Gerry Barron; Stephen A Baldwin; James D Young; Carol E Cass
Journal:  Biochem J       Date:  2006-03-01       Impact factor: 3.857

6.  Identification of Cys140 in helix 4 as an exofacial cysteine residue within the substrate-translocation channel of rat equilibrative nitrobenzylthioinosine (NBMPR)-insensitive nucleoside transporter rENT2.

Authors:  S Y Yao; M Sundaram; E G Chomey; C E Cass; S A Baldwin; J D Young
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

Review 7.  The equilibrative nucleoside transporter family, SLC29.

Authors:  Stephen A Baldwin; Paul R Beal; Sylvia Y M Yao; Anne E King; Carol E Cass; James D Young
Journal:  Pflugers Arch       Date:  2003-06-28       Impact factor: 3.657

8.  Reconstitution of an efficient thymidine salvage pathway in Saccharomyces cerevisiae.

Authors:  Laurence Vernis; Jure Piskur; John F X Diffley
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

9.  Efficient labeling of fission yeast Schizosaccharomyces pombe with thymidine and BUdR.

Authors:  Jeffrey A Hodson; Julie M Bailis; Susan L Forsburg
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

Review 10.  Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling.

Authors:  M Pastor-Anglada; E Errasti-Murugarren; I Aymerich; F J Casado
Journal:  J Physiol Biochem       Date:  2007-03       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.